http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The base of a revised Middle Cambrian: are suitable concepts for a series boundary in reach?
Gerd Geyer 한국지질과학협의회 2005 Geosciences Journal Vol.9 No.2
Defining the base of a series that replaces the traditional Middle Cambrian is among the difficult tasks of Cambrian stratigraphy. Non-traditional concepts (such as carbon isotope signatures), microplankton (such as acritarchs), and most invertebrate fossils (e.g., brachiopods) may act as auxiliary tools for intercontinental correlation of regional calibration but are unable to provide the base for fine-scaled global correlation at present. As a result, the selection of a Global Stratigraphic Section and Point will have to root on trilobites which appear to be the only reliable index fossils to define such a GSSP. Five possible levels of correlation within the traditional Lower-Middle Cambrian boundary interval have been discussed: (1) the FAD of Oryctocephalus indicus; (2) the FAD of Ovatoryctocara granulata and/or Kiskinella cristata; (3) the FAD of Arthricocephalus chauveaui; (4) the base of the Acidiscus-Cephalopyge assemblage "zone"; and (5) the base of the STH "band". The potentials of these levels are analyzed in this study. All of them suffer from certain deficiencies such as limited insight into the stratigraphic ranges of key species; problems of confident identification of the index species; or absence of key faunal elements on certain Cambrian continents; that make them invalid for high-precision correlation on a global scale. However, the combination of (1) through (4) promises an intercontinental correlation that can be used as a global framework, which will be sufficiently accurate to serve normal correlation purposes.
Martin, M.,Bonneterre, J.,Geyer, C.E.,Ito, Y.,Ro, J.,Lang, I.,Kim, S.B.,Germa, C.,Vermette, J.,Wang, K.,Wang, K.,Awada, A. Pergamon Press 2013 European journal of cancer Vol.49 No.18
Background: The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment. Methods: Patients received neratinib 240mg/d continuously (n=117) or lapatinib 1250mg/d continuously plus capecitabine 2000mg/m<SUP>2</SUP> per day on days 1-14 of each 21-d cycle (n=116). The primary aim was to demonstrate non-inferiority of neratinib for progression-free survival (PFS). Findings: The non-inferiority of neratinib was not demonstrated when compared with lapatinib plus capecitabine (hazard ratio, 1.19; 95% confidence interval, 0.89-1.60; non-inferiority margin, 1.15). Median PFS for neratinib was 4.5months versus 6.8months for lapatinib plus capecitabine and median overall survival was 19.7months versus 23.6months. Objective response rate (neratinib, 29% versus lapatinib plus capecitabine, 41%; P=0.067) and clinical benefit rate (44% versus 64%; P=0.003) were lower for the neratinib arm but consistent with previously reported results. In both treatment arms, diarrhoea was the most frequently reported treatment-related adverse event of any grade (neratinib, 85% versus lapatinib plus capecitabine, 68%; P=0.002) and of grade ¾ (28% versus 10%; P<0.001), but was typically managed with concomitant anti-diarrhoeal medication and/or study treatment modification. Importantly, neratinib had no significant skin toxicity. Interpretation: The results are considered as inconclusive since neither inferiority nor non-inferiority of treatment with neratinib versus lapatinib plus capecitabine could be demonstrated. The study confirmed relevant single-agent clinical activity and acceptable overall tolerability of neratinib in patients with recurrent HER2+ advanced breast cancer.
MORPHISMS OF VARIETIES OVER AMPLE FIELDS
Bary-Soroker, Lior,Geyer, Wulf-Dieter,Jarden, Moshe Korean Mathematical Society 2018 대한수학회보 Vol.55 No.4
We strengthen a result of Michiel Kosters by proving the following theorems: (*) Let ${\phi}:W{\rightarrow}V$ be a finite surjective morphism of algebraic varieties over an ample field K. Suppose V has a simple K-rational point a such that $a{\not\in}{\phi}(W(K_{ins}))$. Then, card($V(K){\backslash}{\phi}(W(K))$ = card(K). (**) Let K be an infinite field of positive characteristic and let $f{\in}K[X]$ be a non-constant monic polynomial. Suppose all zeros of f in $\tilde{K}$ belong to $K_{ins}{\backslash}K$. Then, card(K \ f(K)) = card(K).